Selective TAK1 Inhibitor Development
Targeting autoimmune and inflammatory diseases through the use of highly selective protein kinase inhibitors
Unmet Medical Needs
Utilizing our unique discovery platform, we are developing a pipeline of small molecules targeting TAK1 and other disease-driving proteins to provide safer and more effective treatments for patients suffering from various autoimmune and inflammatory diseases of high unmet need
40% of patients need
alternatives to anti-TNF
biologics
TAK1 locally blocks
TNF signaling at the
site of inflammation
As a small molecule,
TAK1 avoids
immune-induced therapy resistance
In vivo oral
bioavailability has been
achieved
In vivo efficacy and
pilot safety are in
progress
Therapeutic Indications
Chronic Pain
Targeting underlying inflammation driving chronic
inflammatory and neuropathic pain
Viral-Induced ARDS
Targeting pulmonary
hyperinflammation due to severe
viral infection
About EydisBio
EydisBio is a small biotech startup based out of Durham, NC focusing on the development of highly selective and potent, novel small molecule kinase inhibitors.
Our current TAK1 program is the first to develop a highly selective orally bioavailable inhibitor of TAK1 for the treatment of inflammatory-mediated diseases. Our proprietary inhibitors represent a novel class of drugs for diseases such as RA, systemic sclerosis, chronic pain, viral-induced ARDS, and SLE.
A word from our president & founder
Timothy Haystead, PhD
Dr. Haystead has extensive experience in all aspects of
small molecule discovery and development. In 2000,
he founded the biotechnology company Serenex, Inc.
which discovered and developed the first orally bioavailable
inhibitor of Hsp90, SNX5422. Read more
Interested in learning more about
our work or partnering with us?
Reach out to our team!
"*" indicates required fields